<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317496</url>
  </required_header>
  <id_info>
    <org_study_id>B9991023</org_study_id>
    <secondary_id>B9991023</secondary_id>
    <secondary_id>2017-001741-27</secondary_id>
    <secondary_id>JAVELIN CHEMOTHERAPY MEDLEY</secondary_id>
    <nct_id>NCT03317496</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies</brief_title>
  <official_title>A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, open label, multicenter, safety and clinical activity study of avelumab
      in combination with chemotherapy as first-line treatment of adult patients with locally
      advanced or metastatic solid tumors. Initially, avelumab will be evaluated in combination
      with pemetrexed and carboplatin in patients with advanced non-squamous non-small cell lung
      cancer (NSCLC) (Cohort A1) and in combination with gemcitabine and cisplatin in patients with
      cisplatin-eligible urothelial (bladder) cancer (UC) (Cohort A2). As more information is
      learned about other anti-cancer immunotherapy agents, in future portions of the study,
      avelumab may be combined with chemotherapy and other anti-cancer immunotherapy agents in
      patients with these same or different tumor types.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, open label, multicenter, safety, clinical activity, pharmacokinetic
      (PK), and pharmacodynamics (PD) study of avelumab in combination with chemotherapy with or
      without other anti-cancer immunotherapies, as first-line treatment of adult patients with
      locally advanced or metastatic solid tumors. Initially, avelumab will be evaluated in
      combination with pemetrexed and carboplatin in patients with advanced non-squamous non-small
      cell lung cancer (NSCLC) (Cohort A1) and with gemcitabine and cisplatin in patients with
      cisplatin-eligible urothelial cancer (UC) (Cohort A2).

      Given the growing preclinical and clinical indications that combinations of anti-cancer
      immunotherapies potentially improve patient outcomes compared to results seen with single
      agents, in portions of the study to be added in the future, avelumab will be evaluated in
      combination with both standard-of-care chemotherapy and other anti-cancer immunotherapies in
      patients with advanced malignancies. Each cohort in the study will consist of a Phase 1b
      lead-in portion to evaluate safety and a Phase 2 cohort expansion to evaluate safety and
      efficacy.

      In the Phase 1b safety lead-in portion, up to 12 patients will be enrolled into each cohort
      and evaluated for dose-limiting toxicities (DLT) during the first 2 cycles of treatment. If
      investigational products administration in a cohort is deemed safe in the Phase 1b lead-in,
      enrollment may be expanded into the Phase 2 cohort expansion. Up to approximately 40 patients
      in each cohort (including those enrolled in the Phase 1b lead-in and those enrolled in the
      Phase 2 cohort expansion) will be enrolled and treated with avelumab plus chemotherapy in the
      initial portion of the study and, in future portions of the study, with avelumab plus
      chemotherapy with or without other anti-cancer immunotherapies.

      In the Phase 1b lead-in portions of NSCLC Cohort A1 and UC Cohort A2, avelumab is dosed at
      800 mg fixed dose every 3 weeks. Under Protocol Amendment 4, avelumab is dosed at 1200 mg
      fixed dose every 3 weeks in the Phase 1b lead-in portions of NSCLC Cohort A3 and in UC Cohort
      A4, in combination with the same standard-of-care chemotherapy doublets used in Cohort A1 and
      Cohort A2, respectively. For each tumor type, the study treatment combination with the
      highest avelumab dose determined to be safe may be advanced into Phase 2 cohort expansion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b lead-in: Number of patients with dose-limiting toxicities in first 2 cycles</measure>
    <time_frame>First 6 weeks of treatment</time_frame>
    <description>Dose-limiting toxicity rate in first 6 (or 12) patients enrolled in safety Phase 1b lead-in of each cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed objective response (OR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>For each cohort, number of patients in the Phase 1b lead-in and Phase 2 cohort expansion with objective response (confirmed complete or partial response) according to RECIST Version 1.1 from the first dose of study treatment until disease progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Progression-Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression by RECIST v1.1 or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Duration of Response (DR) is defined for patients with confirmed objective response (CR or PR) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Time to Tumor Response (TTR) is defined for patients with confirmed objective response (CR or PR) as the time from the first dose of study treatment to the first documentation of objective tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Overall Survival (OS) is defined as the time from the first dose of study treatment to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of cisplatin</measure>
    <time_frame>Day 1 and Day 8 of Cycle 2</time_frame>
    <description>Pharmacokinetic assessment of cisplatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of gemcitabine</measure>
    <time_frame>Day 1 of Cycle 2</time_frame>
    <description>Pharmacokinetic assessment of gemcitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pemetrexed</measure>
    <time_frame>Day 1 and Day 8 of Cycle 2</time_frame>
    <description>Pharmacokinetic assessment of pemetrexed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of carboplatin</measure>
    <time_frame>Day 1 and Day 8 of Cycle 2</time_frame>
    <description>Pharmacokinetic assessment of carboplatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of avelumab</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Day 1 of Cycles 1, 2, 3, 6, 10, and 14, and during the Day 15 visit of Cycles 1, 2, and 3</time_frame>
    <description>Pharmacokinetic assessment of avelumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) levels of avelumab</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 3, 6, 10, and 14, and at End of Treatment</time_frame>
    <description>Immunogenicity assessment of avelumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutational load within baseline tumor tissue</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessment of the number of mutations present per megabase of DNA within the tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 expression in baseline and on-treatment tumor tissue</measure>
    <time_frame>Baseline and Cycle 2 Day 8 (+/- 7 days)</time_frame>
    <description>Assessment of PD-L1 expression in tumor tissue obtained prior to treatment with study drug and while on study treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>Group A Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A Cohort A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A Cohort A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab 800 mg in combination with pemetrexed / carboplatin</intervention_name>
    <description>Avelumab Pemetrexed Carboplatin</description>
    <arm_group_label>Group A Cohort A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab 800 mg in combination with gemcitabine / cisplatin.</intervention_name>
    <description>Avelumab Gemcitabine Cisplatin</description>
    <arm_group_label>Group A Cohort A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab 1200 mg in combination with pemetrexed/carboplatin</intervention_name>
    <description>Avelumab Pemetrexed Carboplatin</description>
    <arm_group_label>Group A Cohort A3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab 1200 mg in combination with gemcitabine/cisplatin</intervention_name>
    <description>Avelumab Gemcitabine Cisplatin</description>
    <arm_group_label>Group A Cohort A4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid
             tumor that is not amenable for treatment with curative intent as follows:

               -  For all groups:

               -  Measurable disease by RECIST v1.1 with at least 1 measurable lesion, and
                  availability of tumor specimen 18 months or less old.

               -  No prior systemic treatment for unresectable locally advanced or metastatic
                  disease for the tumor type under study. If prior systemic chemotherapy treatment
                  was given in the adjuvant or neo-adjuvant setting or as part of radiotherapy
                  chemotherapy treatment, disease-free interval after stop of systemic treatment
                  must be more than 6 months for non-squamous NSCLC and more than 12 months for UC;

               -  Cohort A1 and Cohort A3: Non-squamous NSCLC, with no activating EGFR mutations,
                  ALK or ROS1 translocations/rearrangements. If monotherapy pembrolizumab is
                  available as a standard of care treatment option, patients must have a tumor
                  proportion score (TPS) &lt;50% for PD L1 (via the 22C3 pharmDx or the Ventana
                  (SP263) PD L1 IHC assay).

               -  Cohort A2 and Cohort A4: Transitional cell carcinoma of the urothelium including
                  the bladder, urethra, renal pelvis, and ureter.

          2. ECOG performance status 0 or 1

          3. Estimated life expectancy of at least 90 days

          4. Adequate bone marrow, renal, and liver function

          5. Negative serum pregnancy test at screening

          6. Signed and dated informed consent

        Exclusion Criteria:

          1. Prior immunotherapy with any antibody or drug specifically targeting T cell
             co-stimulation or immune checkpoint pathways.

          2. Patients with known symptomatic central nervous system metastases requiring steroids.

          3. Diagnosis of other malignancy within 2 years prior to enrollment except adequately
             treated basal cell or squamous cell skin cancer, or carcinoma in situ of the bladder,
             breast, or cervix, or low grade (Gleason ≤6) prostate cancer

          4. Use of immunosuppressive medication at the time of enrollment

          5. Active or prior autoimmune disease that might deteriorate when receiving an
             immuno-stimulatory agent.

          6. Prior organ transplantation including allogenic stem cell transplantation

          7. Active infection requiring systemic therapy

          8. Known history of HIV or AIDS

          9. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening

         10. Administration of live vaccine within 4 weeks prior to study entry

         11. Known prior severe hypersensitivity to the investigational products or any component
             in their formulations,

         12. Known prior severe hypersensitivity to platinum-related compounds for all cohorts, to
             pemetrexed for patients enrolled in Cohort A1 and Cohort A3, and to gemcitabine for
             patients enrolled in Cohort A2 and Cohort A4

         13. Persisting toxicity related to prior therapy (NCI CTCAE v4.03 Grade &gt; 1)

         14. Known history of colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis.

         15. Ongoing cardiac dysrhythmias of NCI CTCAE v4.03 Grade 2 or prolongation of the QTcF
             interval to &gt;480 msec.

         16. Clinically significant (ie, active) cardiovascular disease: cerebral vascular
             accident/stroke (&lt;6 months prior to enrollment), myocardial infarction (&lt; 6 months
             prior to enrollment), unstable angina, congestive heart failure, or serious cardiac
             arrhythmia requiring medication.

         17. Major surgery ≤28 days or major radiation therapy ≤14 days prior to enrollment.

         18. Participation in other studies involving investigational drug(s) within 28 days prior
             to study entry.

         19. Concurrent treatment with a prohibited medication.

         20. Other acute or chronic medical or psychiatric condition

         21. Pregnant female patients; breastfeeding female patients; fertile male patients and
             female patients of childbearing potential who are unwilling or unable to use at least
             1 highly effective method of contraception as outlined in this protocol for the
             duration of the study and for at least 90 days after the last dose of chemotherapy
             (for male and female patients) or at least 30 days after the last dose of avelumab
             (for female patients), whichever is longer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - North Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Banner-University Medical Center Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Division</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center/Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Investigational Chemotherapy Service</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Public Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western Health, Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre -</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze, Fakultni poliklinika</name>
      <address>
        <city>Praha 2</city>
        <state>Czech Republic</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc, Klinika nuklearni mediciny</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc, Oddeleni magneticke rezonance (MR)</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc, Oddeleni vypocetni tomografie (CT)</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc, Ustav klinicke a molekularni patologie</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice</name>
      <address>
        <city>Prague</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum nuklearni mediciny s.r.o.</name>
      <address>
        <city>Prague</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice na Bulovce</name>
      <address>
        <city>Prague</city>
        <zip>18081</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum nuklearni mediciny s.r.o.</name>
      <address>
        <city>Prague</city>
        <zip>190 61</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice</name>
      <address>
        <city>Praha 4</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole, Onkologicka klinika</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum nuklearni mediciny s.r.o.</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet &quot;C&quot; Belgyogyaszati - Onkologiai es Klinikai Farmakologiai Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Ospedali Riuniti di Ancona Umberto I - GM Lancisi - G Salesi</name>
      <address>
        <city>Torrette Di Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istit.Scient.Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro di Ricerca di Fase 1, ASST Monza-Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologia, ASST Monza-Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori di Napoli IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Platinum Medical Centre</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW8 7JA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Wellington Hospital - South</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW8 9LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Harley Street Clinic</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HCA Pharmacy Department</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 8HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Harley Street Clinic</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 8PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Princess Grace Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1U 5LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B9991023</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avelumab, immunotherapy, PD-L1 inhibitor, non-small cell lung cancer (NSCLC), urothelial cancer (UC), carboplatin, pemetrexed, gemcitabine, cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

